Eris Lifesciences Ltd · NSE:ERIS

Eris Lifesciences — Q3 FY2019 Earnings Presentation

10 slides from Eris Lifesciences's earnings presentation, January 2019

  1. Slide 1: Q3 19 Investor Presentation

    Eris Q3 19 Investor Presentation

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions

  3. Slide 3: Patient Care Initiatives

    PATIENT CARE INITIATIVES IMPROVING HEALTH OUTCOMES PATIENT CARE – the core of our business model. The aim is to improve health outcomes and the doctor – patient relationship with detailed data Identifying gaps in the healthcare delivery ecosystem and addressing those gaps with unique patient care in

  4. Slide 4: India Heart Study

    INDIA HEART STUDY To generate the first biggest epidemiological data in the country on Office and Home Blood Pressure Measurement 4

  5. Slide 5: Medtronic Partnership

    MEDTRONIC PARTNERSHIP Eris Lifesciences joins hands with Medtronics for diabetes monitoring • In a first of its kind collaboration, Eris Lifesciences has tied up with US medical devices maker Medtronics to bring the latter's technology to test glucose variability in diabetes patients • Medtronic wil

  6. Slide 6: Results Financial Performance: Q3 FY 19

    RESULTS FINANCIAL PERFORMANCE: Q3 FY 19 INR millions Q3 FY 18 Q3 FY 19 yoy GR Sale of Products 2,075 2,485 20% Other Operating Income 15 39 Revenue from Operations 2,090 2,524 21% Gross Profit 1,753 2,130 22% Gross Profit Margins 84% 84% Employee cost 428 475 11% as % of Revenue 20% 19% Other Expens

  7. Slide 7: Results Financial Performance: Q3 FY 19

    RESULTS FINANCIAL PERFORMANCE: Q3 FY 19 INR millions Q3 FY 18 Q3 FY 19 yoy GR Sale of Products 2,075 2,485 20% Other Operating Income 15 39 Revenue from Operations 2,090 2,524 21% EBITDA 811 935 15% EBITDA margin 39% 37% Depreciation and Amortisation * 67 96 43% EBIT 744 839 13% EBIT margin 36% 33%

  8. Slide 8: FY 19 - Growth Trend and Productivity

    FY 19 - Growth Trend and Productivity ERIS Quarterly Revenue INR mn 3,000 2,642 2,491 2,508 2,524 2,500 2,090 2,122 2,000 1,500 1,000 500 - Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 IPM Rank and Productivity IPM Rank * MRs YPM Lacs per month 24 2,022 4.1 Source: Internal numbers 8 * Source: AIOCD AWACS De

  9. Slide 9: Q3 FY 19 Entity Wise Growth

    Q3 FY 19 Entity Wise Growth INR million Q3 FY 19 % of Total yoy GR IPM 3,39,862 100% 10% ERIS Consol 3,061 100% 11% Eris 2,351 77% 14% Strides 535 17% 16% Kinedex 119 4% -35% Aprica 56 2% 14% Source: AIOCD AWACS 9

  10. Slide 10: Thank You

    Eris THANK YOU

Eris Lifesciences — Q3 FY2019 Earnings Presentation on 6ix